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Metastatic Adenocarcinoma of the Prostate to the Brain Initially Diagnosed as Meningioma by
Craniotomy: A Case Report
Julia T Scali, BS; Young Son, DO; Paul Chialastri, DO; Thomas J. Mueller, MD

Rowan University School of Osteopathic Medicine, Urology Department

Introduction
Prostate cancer is the second-leading cause of cancer death in men after
lung cancer. The most common site of prostate metastasis is bone (84%),
lymph node (10.6%), liver (10.2%), and thorax (9.1%), with 18.4% to multiple
metastatic sites [1]. Prostate metastasis to the brain is rare, with less than
1% documented cases from M.D. Anderson Cancer Center [2]. It is
estimated that 1%-6% of prostate cancer metastasis is found in post mortem
examination [3]. Parenchymal brain metastasis has a mean survival of 9.2
months after discovery of brain metastasis [4]. Acute neurological symptoms
of metastatic prostate cancer are observed with metastasis to the lumbar
spine that impinge the spinal cord due to bony lesions. Symptoms of spinal
Figure 1: A. Preoperative transverse CT B. Preoperative transverse
cord compression, urinary retention, and hematuria are commonly seen.
MRI C. Post operative transverse MRI
Conversely, meningioma is a slow-growing, non-infiltrative tumor that
commonly presents with headaches, seizures, and focal neurologic deficits A. Preoperative CT head showing 3.2 cm right anterior frontal mass with
edema. B. Transverse view of preoperative MRI showing 2.8 cm right
depending on location [5]. Prostate cancer is often diagnosed with
anterior frontal extra-axial mass with enhancing dural tail, considered to
neurological symptoms along with increasing prostate specific antigen.
Metastatic prostate cancer presenting with headaches with normal levels of likely be a meningioma. Moderate amount of vasogenic edema was
PSA is a rare presentation. We report a 68-year-old male who presented to considered unusual and raised considerations for other histology such as
the emergency department with a primary complaint of headache and falls oligodendroglioma by radiology. C. Postoperative day-two MRI showing
postsurgical changes and complete removal of mass.
that was initially diagnosed as meningioma with MRI and intraoperative
frozen section that was later confirmed to be metastatic adenocarcinoma of
the prostate on pathology.

Case Presentation
A 68-year-old male presented to the emergency department with headaches,
Figure 2: Posterior View
right-sided weakness, and multiple falls for one-month duration. He was
Bone Scan
noted to have had 45 pounds of unintentional weight loss over the four
Posterior view of bone scan
months prior to presentation. Initial CT of the head showed a 3.2 cm right
showing increased uptake in
frontal mass with edema that was suspicious for meningioma, and the
thoracic and lumbar vertebral
patient was admitted for further investigation and treatment. A metastatic
bodies, sacrum, left humerus,
workup was delayed by the urgent craniotomy due to mass effect at
right femur, and bilateral ribs
presentation. Preoperative workup showed anemia with hemoglobin of 9.7
g/dl, alkaline phosphatase of 144 IU/L, and elevated PSA of 66.7
ng/ml. Digital rectal exam revealed asymmetry of the prostate with an
elevation of the left side of the gland but no discrete nodules. MRI of the
brain showed a 2.8 cm right anterior frontal extra-axial mass with enhancing
dural tail, likely representing meningioma. Additionally, MRI showed
moderate vasogenic edema, raising suspicion for other histology such as
oligodendroglioma (figure 1). Craniotomy was performed with an
intraoperative frozen section initially reported as meningioma, but
subsequently diagnosed as metastatic adenocarcinoma of the prostate on
permanent pathology. Bone scan postoperatively showed increased uptake
in multiple thoracic and lumbar vertebral bodies, sacrum, left humerus, right Differentiating primary brain lesions from metastatic prostate cancer can be
femur, and several bilateral ribs, suspicious for metastatic disease (figure 2.).challenging, especially when a solitary lesion is present. Specific MRI
There was also increased uptake in the right anterior skull, suggestive of
characteristics from metastatic prostate cancer have not been well
postsurgical change. The CT abdomen and pelvis showed patchy sclerosis established in literature; however, some reports describe hemorrhagic brain
throughout the thoracolumbar spine and bony pelvis, suspicious for
metastasis, mixed cystic, solid, or ring-like appearances on MRI.
osteoblastic metastasis. Three weeks later, the patient presented to the
Hemorrhagic brain metastasis is more consistent with renal cell carcinoma,
hospital due to lower extremity edema. At this time repeat PSA was found to melanoma, choriocarcinoma, breast cancer, or thyroid cancer [6]. Of note,
be 118.53, with total testosterone of 144 ng/dL. During the hospital stay
our patient had a negative head CT in December 2018. The rapid growth of
Bicalutamide was initiated and then was followed by Degarelix in the clinic the brain lesion also favors metastasis instead of meningioma as the cause.
one week later. Leuprorelin was subsequently planned for one-month
For our patient, the differential diagnosis of meningioma with edema was
postoperatively and followed up with WBRT.
initially explored and then falsely positive confirmed with a frozen tissue

Discussion

sample biopsy. The initial sample did stain for meningioma.
Our patient’s PSA of 66.7 ng/ml qualifies for a bone scan for metastasis;
however, the patient’s indolent course of prostate cancer was only detected
at the time of extensive metastasis without causing lower urinary tract
symptoms or other neurological symptoms usually seen with metastatic
prostate cancer. Additionally, the patient’s previous PSA levels of 1.14 ng/ml
in 2008, 0.91 ng/ml in 2011, and 1.18 ng/ml in 2013, along with the absence
of symptoms, showed no indication for a bone scan. This patient's
intraoperative frozen pathology was reported as meningioma, but later was
documented as “cannot rule out malignancy.” Permanent pathology stained
positive for PSA and PSAP, supporting metastatic adenocarcinoma of
prostatic origin as the diagnosis.
Brain biopsy is not recommended in metastatic prostatic disease. Although
histopathology is the confirmatory test of choice, it is unnecessary in patients
with poor prognoses. In our patient, the diagnosis of brain metastasis was
confirmed post resection of brain tumor. With headache as the presenting
problem, a primary brain tumor was more probable than metastatic disease.
Routine head imaging is also not performed in patients with prostate cancer.
Historically, it has been reported that solitary brain metastasis has been
treated with craniotomy with resection followed by radiation therapy with
possible WBRT [7]. Androgen deprivation therapy with Bicalutamide and
Degarelix was initiated with systemic chemotherapy to follow. Currently,
Enzalutamide is the most commonly prescribed compound for treatment of
metastatic castration-resistant prostate cancer. However, its use may be
contraindicated in patients with brain metastasis since it potentiates seizures
by crossing the blood-brain barrier. There are other antiandrogens, such as
Abiraterone and Apalutimide, which are approved for use in metastatic
prostate cancer, but with less passage through the blood-brain barrier,
theorizing their limited use in brain metastasis [8]. Cabazetaxel has shown to
improve passage through the blood-brain barrier compared to
Docetaxel [9]. Chemotherapy will be followed up by WBRT recommended by
radiology oncology.

Conclusions
Metastatic prostate cancer presenting as headaches due to metastasis to
the brain is a rare finding that can occur at relatively low PSA levels. In
patients of appropriate demographics and with abnormal digital rectal
exams, differential diagnosis of prostate cancer must be explored even with
imaging or histopathology that does not represent metastatic disease.
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